Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 28 | 2023 | 100 | 11.330 |
Why?
|
| Adenoma | 15 | 2023 | 56 | 8.280 |
Why?
|
| Colonoscopy | 26 | 2023 | 62 | 6.440 |
Why?
|
| Colonic Polyps | 11 | 2023 | 28 | 4.890 |
Why?
|
| Early Detection of Cancer | 13 | 2023 | 90 | 3.240 |
Why?
|
| Neoplasms, Second Primary | 5 | 2022 | 37 | 2.770 |
Why?
|
| DNA Methylation | 5 | 2022 | 139 | 1.850 |
Why?
|
| Barrett Esophagus | 4 | 2020 | 13 | 1.720 |
Why?
|
| Capsule Endoscopy | 2 | 2021 | 2 | 1.430 |
Why?
|
| Long Interspersed Nucleotide Elements | 2 | 2021 | 5 | 1.310 |
Why?
|
| Esophagoscopy | 5 | 2021 | 13 | 1.140 |
Why?
|
| Humans | 48 | 2023 | 25692 | 1.140 |
Why?
|
| Population Surveillance | 3 | 2018 | 103 | 1.090 |
Why?
|
| Adenomatous Polyps | 3 | 2017 | 4 | 1.080 |
Why?
|
| Endoscopy, Gastrointestinal | 3 | 2021 | 10 | 1.080 |
Why?
|
| Mass Screening | 5 | 2023 | 168 | 1.050 |
Why?
|
| Guideline Adherence | 2 | 2016 | 59 | 0.990 |
Why?
|
| Esophageal Neoplasms | 3 | 2020 | 49 | 0.920 |
Why?
|
| Diagnostic Errors | 2 | 2014 | 29 | 0.870 |
Why?
|
| Middle Aged | 20 | 2021 | 8403 | 0.860 |
Why?
|
| Gastroenterology | 3 | 2019 | 10 | 0.820 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2022 | 2 | 0.790 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2022 | 22 | 0.770 |
Why?
|
| Intestine, Small | 1 | 2021 | 25 | 0.730 |
Why?
|
| Aged | 18 | 2021 | 8501 | 0.690 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2020 | 3 | 0.690 |
Why?
|
| Carcinoma | 2 | 2022 | 63 | 0.690 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 132 | 0.660 |
Why?
|
| Quality of Health Care | 2 | 2022 | 117 | 0.660 |
Why?
|
| No-Show Patients | 1 | 2019 | 1 | 0.650 |
Why?
|
| Censuses | 1 | 2019 | 7 | 0.640 |
Why?
|
| Poverty Areas | 1 | 2019 | 8 | 0.640 |
Why?
|
| Male | 19 | 2021 | 13917 | 0.630 |
Why?
|
| Female | 19 | 2021 | 14273 | 0.620 |
Why?
|
| Pancreatic Neoplasms | 2 | 2020 | 89 | 0.580 |
Why?
|
| Residence Characteristics | 1 | 2019 | 183 | 0.570 |
Why?
|
| Esophagus | 2 | 2021 | 62 | 0.570 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 23 | 0.570 |
Why?
|
| Retrospective Studies | 9 | 2023 | 3220 | 0.550 |
Why?
|
| Clinical Competence | 2 | 2016 | 217 | 0.550 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 33 | 0.550 |
Why?
|
| Cecum | 1 | 2016 | 13 | 0.550 |
Why?
|
| Colon | 3 | 2016 | 131 | 0.550 |
Why?
|
| Lymphoid Tissue | 1 | 2016 | 9 | 0.540 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 24 | 0.530 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 37 | 0.520 |
Why?
|
| Biopsy | 5 | 2021 | 199 | 0.510 |
Why?
|
| Colorectal Surgery | 1 | 2015 | 2 | 0.490 |
Why?
|
| Colonic Neoplasms | 3 | 2022 | 56 | 0.490 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 25 | 0.490 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 184 | 0.480 |
Why?
|
| Risk Factors | 5 | 2021 | 2224 | 0.460 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 107 | 0.450 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 11 | 0.450 |
Why?
|
| Intestines | 1 | 2014 | 88 | 0.440 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 284 | 0.390 |
Why?
|
| Prospective Studies | 5 | 2023 | 1633 | 0.380 |
Why?
|
| Colectomy | 1 | 2010 | 23 | 0.350 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 315 | 0.340 |
Why?
|
| Colitis, Ulcerative | 1 | 2010 | 61 | 0.340 |
Why?
|
| Hyperplasia | 2 | 2021 | 17 | 0.320 |
Why?
|
| Incidence | 3 | 2019 | 731 | 0.290 |
Why?
|
| Cohort Studies | 4 | 2018 | 1781 | 0.270 |
Why?
|
| Area Under Curve | 2 | 2019 | 55 | 0.270 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2023 | 2 | 0.270 |
Why?
|
| United States | 3 | 2020 | 1943 | 0.240 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 119 | 0.240 |
Why?
|
| Intestinal Polyposis | 1 | 2023 | 1 | 0.230 |
Why?
|
| Hyperthermia, Induced | 1 | 2023 | 6 | 0.220 |
Why?
|
| Surgical Instruments | 1 | 2023 | 18 | 0.210 |
Why?
|
| Risk Assessment | 3 | 2020 | 618 | 0.210 |
Why?
|
| Esophageal pH Monitoring | 1 | 2021 | 2 | 0.190 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 126 | 0.190 |
Why?
|
| MicroRNAs | 1 | 2022 | 52 | 0.190 |
Why?
|
| Zenker Diverticulum | 1 | 2021 | 1 | 0.190 |
Why?
|
| Endosonography | 2 | 2020 | 11 | 0.190 |
Why?
|
| Gastrointestinal Transit | 1 | 2021 | 9 | 0.190 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 22 | 0.180 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 16 | 0.180 |
Why?
|
| Pancreatitis, Chronic | 1 | 2020 | 1 | 0.180 |
Why?
|
| Logistic Models | 2 | 2013 | 366 | 0.180 |
Why?
|
| Pancreatic Cyst | 1 | 2020 | 5 | 0.180 |
Why?
|
| Observer Variation | 1 | 2021 | 100 | 0.180 |
Why?
|
| Ikaros Transcription Factor | 1 | 2020 | 2 | 0.180 |
Why?
|
| Circulating Tumor DNA | 1 | 2020 | 4 | 0.180 |
Why?
|
| Transaminases | 1 | 2020 | 6 | 0.180 |
Why?
|
| Gastroparesis | 1 | 2020 | 2 | 0.180 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4459 | 0.180 |
Why?
|
| Feasibility Studies | 1 | 2021 | 207 | 0.170 |
Why?
|
| Magnets | 1 | 2020 | 3 | 0.170 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 6 | 0.170 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 45 | 0.170 |
Why?
|
| Databases, Factual | 1 | 2021 | 329 | 0.170 |
Why?
|
| Treatment Outcome | 3 | 2023 | 3231 | 0.160 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 14 | 0.160 |
Why?
|
| Quality Improvement | 1 | 2020 | 132 | 0.160 |
Why?
|
| ROC Curve | 1 | 2019 | 129 | 0.160 |
Why?
|
| Simulation Training | 1 | 2019 | 35 | 0.160 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2018 | 2 | 0.160 |
Why?
|
| Forecasting | 1 | 2019 | 92 | 0.160 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 646 | 0.160 |
Why?
|
| Genetic Testing | 1 | 2018 | 56 | 0.150 |
Why?
|
| Colonoscopes | 1 | 2018 | 1 | 0.150 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 76 | 0.150 |
Why?
|
| Referral and Consultation | 1 | 2018 | 86 | 0.140 |
Why?
|
| Prognosis | 3 | 2018 | 739 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 55 | 0.140 |
Why?
|
| CpG Islands | 1 | 2017 | 43 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 26 | 0.140 |
Why?
|
| Gastroenterologists | 1 | 2016 | 3 | 0.140 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 75 | 0.130 |
Why?
|
| Portal Vein | 1 | 2017 | 43 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 1 | 2017 | 68 | 0.130 |
Why?
|
| Documentation | 1 | 2016 | 25 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 57 | 0.130 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 93 | 0.130 |
Why?
|
| Hospitals, Community | 1 | 2015 | 12 | 0.120 |
Why?
|
| Rectal Neoplasms | 1 | 2015 | 13 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2013 | 532 | 0.120 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 472 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 847 | 0.120 |
Why?
|
| Metaplasia | 1 | 2014 | 3 | 0.120 |
Why?
|
| Microsatellite Instability | 1 | 2014 | 9 | 0.120 |
Why?
|
| Stomach | 1 | 2014 | 15 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 443 | 0.120 |
Why?
|
| Adult | 4 | 2020 | 7336 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2016 | 196 | 0.110 |
Why?
|
| Intestinal Mucosa | 3 | 2022 | 178 | 0.110 |
Why?
|
| Mast Cells | 1 | 2013 | 16 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 41 | 0.100 |
Why?
|
| Colitis | 1 | 2013 | 36 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2013 | 72 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 51 | 0.100 |
Why?
|
| Macrophages | 1 | 2013 | 97 | 0.100 |
Why?
|
| Time Factors | 1 | 2016 | 1336 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 698 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 119 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 1689 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 341 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1300 | 0.070 |
Why?
|
| Reoperation | 1 | 2010 | 818 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 75 | 0.060 |
Why?
|
| Fecal Incontinence | 1 | 2005 | 3 | 0.060 |
Why?
|
| Geriatric Assessment | 1 | 2005 | 195 | 0.060 |
Why?
|
| Occult Blood | 1 | 2023 | 3 | 0.050 |
Why?
|
| Feces | 1 | 2023 | 103 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2022 | 24 | 0.050 |
Why?
|
| Manometry | 1 | 2021 | 14 | 0.050 |
Why?
|
| Endoscopes | 1 | 2021 | 9 | 0.050 |
Why?
|
| Pyloromyotomy | 1 | 2020 | 1 | 0.040 |
Why?
|
| Pylorus | 1 | 2020 | 1 | 0.040 |
Why?
|
| Gastric Emptying | 1 | 2020 | 11 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 8 | 0.040 |
Why?
|
| Gastroplasty | 1 | 2020 | 22 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 56 | 0.040 |
Why?
|
| Inventions | 1 | 2019 | 2 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 6 | 0.040 |
Why?
|
| Biomedical Technology | 1 | 2019 | 8 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 48 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 29 | 0.040 |
Why?
|
| Gastric Bypass | 1 | 2020 | 61 | 0.040 |
Why?
|
| Watchful Waiting | 1 | 2019 | 10 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 32 | 0.040 |
Why?
|
| Models, Anatomic | 1 | 2019 | 43 | 0.040 |
Why?
|
| Virtual Reality | 1 | 2019 | 13 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 198 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 2020 | 87 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2019 | 89 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 85 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 24 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2019 | 138 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 96 | 0.040 |
Why?
|
| Videotape Recording | 1 | 2018 | 24 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 217 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 332 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 98 | 0.040 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2017 | 1 | 0.040 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 1 | 0.040 |
Why?
|
| Portal Pressure | 1 | 2017 | 5 | 0.040 |
Why?
|
| Sex Factors | 1 | 2018 | 427 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2017 | 12 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 6 | 0.040 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2017 | 5 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 664 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 716 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 600 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 12 | 0.030 |
Why?
|
| ras Proteins | 1 | 2014 | 9 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 20 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 31 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 84 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 95 | 0.030 |
Why?
|
| Piroxicam | 1 | 2013 | 4 | 0.030 |
Why?
|
| Tryptases | 1 | 2013 | 4 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2013 | 7 | 0.030 |
Why?
|
| Chromones | 1 | 2013 | 7 | 0.030 |
Why?
|
| Cell Degranulation | 1 | 2013 | 5 | 0.030 |
Why?
|
| Morpholines | 1 | 2013 | 11 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 16 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 31 | 0.030 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2013 | 27 | 0.030 |
Why?
|
| Cell Movement | 1 | 2013 | 70 | 0.030 |
Why?
|
| Mutation | 1 | 2014 | 325 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 221 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2013 | 167 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2013 | 284 | 0.020 |
Why?
|
| Rectum | 1 | 2011 | 43 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 89 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 405 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 410 | 0.020 |
Why?
|
| Mice | 1 | 2013 | 1345 | 0.020 |
Why?
|
| Animals | 1 | 2013 | 3510 | 0.020 |
Why?
|
| Causality | 1 | 2005 | 55 | 0.020 |
Why?
|
| Psychotropic Drugs | 1 | 2005 | 27 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2005 | 110 | 0.010 |
Why?
|
| Health Surveys | 1 | 2005 | 85 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 129 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 457 | 0.010 |
Why?
|
| Chicago | 1 | 2005 | 869 | 0.010 |
Why?
|
| Stroke | 1 | 2005 | 259 | 0.010 |
Why?
|